| Press releases

Formycon ends 2015 fiscal year with successful results

Formycon has ended the 2015 financial year with both operational and financial success. In the last year, Formycon has made great strides with the initiation of the clinical Phase III study involving the biosimilar candidate FYB201 (ranibizumab) in particular.


BioProcess International Europe Conference

Speaker: Carsten Brockmeyer, PhD
Date: April 12 - 13, 2016
Location: Vienna, Austria

Financial reports

Annual report 2014

Published on 19. May 2015

  • buchner_en
  • slider02
  • slider03
  • slider04
  • slider05
  • slider06

Formycon is a leading independent pure play developer of biosimilars and has become a recognized innovator in this field. The company has extensive experience in the development of complex biological molecules. Formycon’s specialist expertise allows the company to develop high-quality biosimilars that meet the strict regulatory requirements of highly regulated markets such as Europe and the United States. Formycon currently has three biosimilars under development, with further product candidates already identified. Two biosimilar candidates have been licensed out to Santo Holding GmbH.